Search results
Results from the WOW.Com Content Network
CRISPR gene editing (CRISPR, pronounced / ˈ k r ɪ s p ə r / (crisper), refers to a clustered regularly interspaced short palindromic repeats") is a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified.
Cas9 (or "CRISPR-associated protein 9") is an enzyme that uses CRISPR sequences as a guide to recognize and open up specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within living organisms.
The company was founded in 2017 [3] by Jennifer Doudna, Janice Chen, and Lucas Harrington of the University of California, Berkeley, and Trevor Martin of Stanford University. [4] Mammoth signed agreements in December 2019 and January 2020 with Horizon Discovery to combine Mammoth's intellectual property in CRISPR with Horizon's expertise in ...
The company has previously developed vaccines for avian flu, including one used by the US Fish and Wildlife Service to protect California condors in 2023, Zoetis said, noting, “The decision to ...
(Reuters) -Twenty-four companies are working to develop an avian flu vaccine for cattle, as the virus spreads among U.S. dairy herds, Agriculture Secretary Tom Vilsack told Reuters on Wednesday.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.
Zoetis Inc. (/zō-EH-tis/ [4]) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. [5] [4] [6] The company was a subsidiary of Pfizer, [7] the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company.
CRISPR technology is a promising tool not only for genetic disease corrections but also for the prevention of viral and bacterial infections. Utilizing CRISPR–Cas therapies, researchers have targeted viral infections like HSV-1, EBV, HIV-1, HBV, HPV, and HCV, with ongoing clinical trials for an HIV-clearing strategy named EBT-101 ...